Fulcrum Therapeutics (NASDAQ:FULC) Rating Lowered to “Hold” at Cantor Fitzgerald

Fulcrum Therapeutics (NASDAQ:FULC) was downgraded by analysts at Cantor Fitzgerald from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. Citigroup downgraded shares of Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research note on Tuesday. Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 2nd. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 target price for the company. in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Tuesday, April 21st. Finally, Truist Financial reissued a “hold” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Tuesday. Two research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Fulcrum Therapeutics has a consensus rating of “Reduce” and an average target price of $8.20.

Fulcrum Therapeutics Stock Down 51.1%

Shares of Fulcrum Therapeutics stock opened at $3.14 on Tuesday. The company has a market capitalization of $209.22 million, a price-to-earnings ratio of -2.73 and a beta of 2.93. Fulcrum Therapeutics has a 12-month low of $2.83 and a 12-month high of $15.74. The firm’s 50-day moving average price is $7.23 and its two-hundred day moving average price is $9.22.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. On average, sell-side analysts expect that Fulcrum Therapeutics will post -1.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in Fulcrum Therapeutics in the 4th quarter valued at approximately $30,000. Meeder Asset Management Inc. bought a new position in Fulcrum Therapeutics in the 4th quarter valued at approximately $39,000. Quarry LP bought a new position in Fulcrum Therapeutics in the 3rd quarter valued at approximately $35,000. Persistent Asset Partners Ltd bought a new position in Fulcrum Therapeutics in the 4th quarter valued at approximately $75,000. Finally, Summit Securities Group LLC bought a new position in Fulcrum Therapeutics in the 1st quarter valued at approximately $53,000. Institutional investors own 89.83% of the company’s stock.

Trending Headlines about Fulcrum Therapeutics

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Positive Sentiment: Fulcrum said it will explore strategic alternatives, including a potential sale or merger, which could unlock value if a transaction emerges.
• Neutral Sentiment: Leerink Partners reaffirmed a market perform rating and set a $4 price target, while Stifel kept a hold rating with a $3 target.
• Negative Sentiment: The company discontinued pociredir after FDA concerns over cancer risk, removing its lead program and raising doubts about Fulcrum’s long-term pipeline. Article Title
• Negative Sentiment: Multiple law firms launched investigations into possible securities law violations following the stock’s collapse, adding legal overhang. Article Title

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.